Muscle Relaxants —
Antispasmodics vs Antispastics

Cyclobenzaprine is the most frequently prescribed skeletal muscle relaxant in the United States, and understanding why requires understanding what it pharmacologically resembles: it is structurally and mechanistically very similar to tricyclic antidepressants (TCAs) like amitriptyline. It is not a TCA — it does not have meaningful antidepressant efficacy — but it carries the same sedation, anticholinergic burden, and cardiac conduction risks that make TCAs difficult in certain populations.

The drug acts primarily at the level of the brainstem, reducing the tonic somatic motor activity that drives muscle spasm. It does not act at the neuromuscular junction and has no direct effect on skeletal muscle fibers. Its significant sedation is often considered part of its therapeutic effect — a patient with acute back spasm who sleeps through the night may have better recovery than one who does not — but it also limits daytime function and driving.

The IR formulation (typically 5–10mg) has a long half-life of 18–37 hours despite being called "immediate release," meaning it accumulates with repeated dosing. The ER formulation (Amrix, 15–30mg) is taken once daily and produces more consistent blood levels. Cyclobenzaprine is only proven effective for acute spasm and should generally not be used beyond 2–3 weeks. No high-quality evidence supports benefit beyond this window.

Methocarbamol is a carbamate compound with CNS-depressant properties, though its precise mechanism of action in reducing muscle spasm is not fully established. It is generally considered less sedating than cyclobenzaprine and carries a much lower anticholinergic burden, making it a more tolerable option for patients who cannot accept significant sedation — people who must drive, work, or manage family responsibilities during acute treatment.

Methocarbamol is renally cleared and can be used in mild-to-moderate renal impairment with monitoring; it does not rely heavily on hepatic metabolism, which distinguishes it from some other agents in this class. It is available in 500mg and 750mg tablets, and the injectable form is used in emergency settings for acute muscle spasm and tetanus.

A notable and clinically benign but alarming side effect: methocarbamol can turn urine brown, black, or greenish upon standing. Patients should be informed of this before starting the medication; many who are not warned discontinue prematurely assuming it signals kidney damage. It does not. The discoloration is a metabolite of the drug and resolves when the medication is stopped.

Carisoprodol occupies a uniquely controversial position among muscle relaxants. The drug itself acts as a CNS depressant to reduce acute muscle spasm, but its clinical profile is largely determined by what happens after it is absorbed: the liver metabolizes a substantial fraction of each dose into meprobamate, a Schedule IV controlled substance that acts as a GABA-A positive modulator with significant anxiolytic, sedative, and abuse potential. In effect, patients taking carisoprodol are also receiving an active anxiolytic at every dose.

Meprobamate was widely prescribed in the 1950s–60s ("Miltown," the first mass-market anti-anxiety drug) before being displaced by benzodiazepines when meprobamate's dependence potential and overdose risk became better understood. Its resurgence as the metabolite of a prescribed muscle relaxant means these risks re-enter through a different formulation. Physical dependence can develop with regular carisoprodol use; withdrawal can be severe, including seizures.

Carisoprodol is classified Schedule IV in the US (since 2012). It has a documented pattern of misuse, particularly in a three-drug combination with opioids and benzodiazepines that has acquired street names ("Holy Trinity," "Las Vegas Cocktail") due to the potentiated euphoria and sedation — a combination that dramatically increases respiratory depression risk. Many prescribers now avoid carisoprodol entirely given the availability of safer alternatives.

Metaxalone is often preferred when sedation is a primary concern. It produces less CNS depression than cyclobenzaprine or carisoprodol, which allows it to be used with a more reasonable expectation that patients can function during the day. The mechanism is not fully characterized — it appears to depress spinal cord polysynaptic reflexes through CNS depression, like other agents in this class — but the degree of sedation is reliably lower in clinical practice.

A distinctive pharmacokinetic feature: food substantially increases metaxalone's bioavailability, often doubling the area under the curve compared to fasted administration. This is clinically relevant because patients who take the medication without food may receive a subtherapeutic dose, while those who take it consistently with food will have meaningfully higher exposures. Patients should be counseled to be consistent — take it the same way (with or without food) each time, ideally as prescribed.

Metaxalone undergoes significant hepatic metabolism, and its use is contraindicated in patients with significant hepatic impairment. Periodic liver enzyme monitoring is recommended with long-term use, though the drug is typically prescribed short-term. Drug interactions are relatively limited compared to other agents in this class, which simplifies its use in patients on multiple medications.

Chlorzoxazone is one of the oldest agents in the antispasmodic class, introduced in the 1950s. It acts at the level of the spinal cord and subcortical brain areas to inhibit the polysynaptic reflex arcs involved in skeletal muscle spasm, producing its CNS-depressant effect. It is significantly less commonly prescribed today than cyclobenzaprine or methocarbamol, partly due to a concerning, if rare, hepatotoxicity signal.

The drug is a substrate of CYP2E1, the same enzyme responsible for metabolizing alcohol and some solvents. This makes it susceptible to drug interactions with CYP2E1 inhibitors (disulfiram, for example) and inducers. Alcohol substantially impairs the enzyme pathway that metabolizes chlorzoxazone, potentially increasing exposure. The CYP2E1 substrate status also underlies some of the hepatotoxicity risk — reactive intermediates generated by this enzyme can contribute to hepatocellular damage in susceptible patients.

Like methocarbamol, chlorzoxazone produces a harmless but disconcerting urine discoloration — an orange or reddish-orange color caused by metabolites excreted in urine. Patients should be warned of this before starting the medication. Liver function should be monitored with any extended use, and the medication should be discontinued immediately if signs of hepatic injury (jaundice, abdominal pain, dark urine, elevated transaminases) develop.

Orphenadrine is a first-generation antihistamine derivative with anticholinergic properties — it is structurally related to diphenhydramine (Benadryl). Its muscle-relaxing effect stems from CNS depression and a reduction in spinal cord reflex excitability. Unlike most other antispasmodics, orphenadrine also has weak analgesic properties via NMDA receptor antagonism, which makes it useful in combination with NSAIDs for pain-dominant presentations — the Norgesic formulation pairs orphenadrine with aspirin for exactly this reason.

Its anticholinergic profile is pronounced: dry mouth, blurred vision, urinary retention, constipation, and tachycardia are expected side effects and become clinically significant in populations with baseline vulnerability. Patients with benign prostatic hyperplasia (BPH), narrow-angle glaucoma, myasthenia gravis, or cardiac arrhythmias should generally not receive orphenadrine. The drug is explicitly included on the Beers Criteria list due to its anticholinergic burden in older adults and the increased risk of delirium, falls, and urinary retention in this population.

An injectable (IV/IM) formulation of orphenadrine exists for use in acute settings when oral administration is not possible, distinguishing it from most other antispasmodics which are oral-only. This can be clinically useful in emergency or perioperative contexts for acute muscle spasm management.